{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "MRK",
  "name": "Merck & Co., Inc.",
  "url": "https://frontierpicks.com/dossiers/MRK/",
  "json_url": "https://frontierpicks.com/dossiers/MRK.json",
  "status": "WATCHLIST",
  "current_conviction": "MEDIUM",
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Merck's newer drugs, led by Winrevair's 75% second-quarter sales growth and the July launch of the oral cholesterol pill Lipfendra, are reducing its reliance on Keytruda. The 29 October 2026 third-quarter report shows whether sales confirm the raised $66.3–67.3 billion full-year range.",
  "invalidation_trigger": "A daily close below $134, which would undo a large part of the three-month advance; or a 2026-10-29 third-quarter report that cuts the $66.3–67.3 billion full-year 2026 sales range.",
  "catalyst_date": "2026-10-29",
  "pick": {
    "id": "P-2026-10-01-MRK",
    "conviction": "MEDIUM",
    "status": "open",
    "opened": "2026-10-01",
    "open_close": 143.81,
    "kill_level": 134,
    "kill_basis": "daily",
    "horizon_end": "2026-12-31",
    "last_date": "2026-10-09",
    "last_close": 145.6,
    "return_pct": 1.24,
    "spy_return_pct": 1.91,
    "excess_pp": -0.66,
    "kill_distance_pct": 8.656716417910438,
    "closed": null,
    "close_reason": null,
    "outcome": null,
    "scoreboard": "https://frontierpicks.com/track-record/"
  },
  "themes": [
    "oncology-immunology",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Merck & Co. operates as MSD outside the United States and Canada; it is a separate company from Germany's Merck KGaA, which operates as EMD in North America.",
    "Merck's adjusted (non-GAAP) earnings guidance includes one-time acquisition and licensing charges, so year-over-year EPS comparisons can swing widely after large deals.",
    "The under-the-skin form of Keytruda is subject to Halozyme patent litigation in Germany, the Netherlands-based European case and US federal court in New Jersey."
  ],
  "body_markdown": "## Current Thesis\nMerck's newer medicines are growing fast enough to start reducing its dependence on Keytruda, and the third-quarter report on 2026-10-29 settles the next step of the case. That report shows whether sales track the raised full-year 2026 range of $66.3–67.3 billion. It also gives the first full quarter of sales for Lipfendra, the oral cholesterol pill the Food and Drug Administration (FDA) approved on 2026-07-16.\n\nSince the last update, the new facts are mixed. On 2026-10-07 a Dutch patent court barred Merck's European unit from making or selling the under-the-skin form of Keytruda in eight European markets, per Halozyme and pharmaphorum. On the other side, Cantor Fitzgerald raised its target on 2026-10-08, and Morgan Stanley kept an Overweight rating despite a lower target. Neither change touches the near-term question, which is whether Winrevair, Welireg, Capvaxive and Lipfendra keep growing in the third quarter.\n\nKeytruda and its under-the-skin form, Keytruda Qlex, brought in $8.4 billion of that, also up 5%. Winrevair rose 75% to $588 million, Welireg rose 67% to $271 million and Capvaxive rose 42% to $184 million.\n\n## Bull Case\n- **Newer products are growing fast.** Winrevair sales rose 75% and Welireg sales rose 67% in the second quarter of 2026, per Merck's 2026-08-04 results.\n- **Merck raised its revenue outlook.** On 2026-08-04 Merck lifted full-year 2026 sales guidance to $66.3–67.3 billion, from $65.8–67.0 billion.\n- **A new heart-health product is launching.** The FDA approved Lipfendra (enlicitide) on 2026-07-16; Merck calls it the first once-daily oral PCSK9 inhibitor for lowering LDL cholesterol. It cut LDL cholesterol by 56% against placebo at week 24 in the Phase 3 CORALreef Lipids trial, per Merck.\n- **A dense month of regulatory wins.** The FDA approved Welireg plus Lenvima for advanced kidney cancer on 2026-09-24 and updated Winrevair's label on 2026-09-22 using the Phase 3 HYPERION trial. Japan approved Keytruda Qlex for all existing Keytruda uses on 2026-09-21.\n- **Positive mid-stage immunology data.** On 2026-09-30 Merck said tulisokibart met its Phase 2b primary endpoint in hidradenitis suppurativa, a chronic skin disease, with response rates of 72% and 64% at two doses against 35% for placebo at week 16.\n- **Cancer vaccine work is moving toward launch.** Tempus said on 2026-10-07 it expanded its collaboration with Merck and Moderna to support sample collection and genetic sequencing for the potential commercialization of the cancer vaccine intismeran autogene alongside Keytruda; terms were not disclosed.\n- **Most analyst targets sit above the share price.** JPMorgan raised its target to $165 from $150 on 2026-10-05, and Scotiabank raised its target to $180 from $155 on 2026-09-29. Morgan Stanley lowered its target to $177 on 2026-10-07 but kept an Overweight rating, per Benzinga.\n\n## Bear Case\n- **Keytruda still dominates sales.** Keytruda and Keytruda Qlex made up $8.4 billion of $16.6 billion in second-quarter 2026 sales, per Merck. Its patent expiry is the central long-term risk for the company.\n- **A patent ruling blocks the new Keytruda form in Europe.** On 2026-10-07 the Hague patent court found Merck infringed Halozyme's patent EP 2,797,622 and barred the under-the-skin form of Keytruda in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands, per Halozyme. A German court already blocked it on 2025-12-04, and Halozyme is also suing in US federal court in New Jersey. The intravenous form stays available. The under-the-skin form sold $463 million worldwide in the second quarter, per pharmaphorum.\n- **A vaccine rival posted Phase 3 data.** Vaxcyte said on 2026-10-05 that VAX-31 met noninferiority against Capvaxive on 17 of 19 shared serotypes in the 4,047-person OPUS-1 trial. Vaxcyte plans its US filing in the first half of 2028.\n- **Deal charges halved the profit outlook.** On 2026-08-04 Merck cut full-year non-GAAP (adjusted) earnings-per-share guidance to $2.66–2.76 from $5.04–5.16, mainly on a $2.31 per share charge for the Terns acquisition.\n- **A late-stage cancer filing was withdrawn.** Merck and Daiichi Sankyo withdrew the US application for ifinatamab deruxtecan in small cell lung cancer on 2026-09-25 after FDA feedback on Phase 2 data.\n- **Some analysts see little upside.** Cantor Fitzgerald kept a Neutral rating while raising its target to $145 on 2026-10-08, per Benzinga, close to the $142.38 close that day.\n\n## Setup & Price Structure\nThe shares closed at $142.38 on 2026-10-08 on adjusted daily closes, 8.5% below the 52-week high of $155.53 and 15.5% higher over three months. The 14-day relative strength index (RSI), a momentum gauge running from 0 to 100, stood at 40.2, which points to fading short-term momentum without an oversold reading.\n\nThe $134 level marks the point where a large part of the three-month advance would be undone. A close there would show the market discounting the newer-product story ahead of, or in response to, the third-quarter report. The observable crowding signal is the earnings date 20 days out; the shares sit below their high and momentum has cooled.\n\n## Catalyst Calendar (next 30 days)\n- **2026-10-26 — Merck investor event at the ESMO 2026 oncology congress.** It shows how management frames the cancer pipeline after the 2026-09-25 withdrawal and the 2026-10-07 European patent ruling.\n- **2026-10-29 — Third-quarter 2026 sales and earnings report, call at 9:00 a.m. ET, per Merck.** It shows whether Winrevair, Welireg and Capvaxive keep growing, gives the first full-quarter read on Lipfendra, and confirms or cuts the $66.3–67.3 billion sales range. It may also give Merck's first quantified view of the European patent ruling.\n\n## What Would Change Our Mind\nThe case breaks if the 2026-10-29 report cuts the $66.3–67.3 billion full-year sales range, or if Winrevair and Welireg growth slows sharply from the second quarter's 75% and 67%. A daily close below $134 would also end it, because that would undo a large part of the three-month advance.\n\nA wider loss on the Halozyme patents, such as a US court injunction against Keytruda Qlex, would weaken the plan to move patients to the under-the-skin form before Keytruda's patents expire. Another withdrawn filing or failed Phase 3 trial in a late-stage cancer program would weaken it further.\n\n## Correlation Notes\nMerck trades with large US drugmakers and the defensive health-care sector, so sector rotation into or out of defensive stocks moves it alongside peers. Company-specific swings now come from competitor and legal news: Vaxcyte's pneumococcal vaccine data, PD-1/VEGF cancer drugs such as Summit and Akeso's ivonescimab, and Halozyme's patent cases. Halozyme shares tend to move opposite Merck on rulings in that dispute.",
  "first_seen": "2026-10-01",
  "last_analyzed": "2026-10-09T08:34:46+00:00",
  "last_synthesized": "2026-10-09",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}